Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab + TAS-102 in RAS Wild-type Metastatic Colorectal Cancer
NCT02613221Phase 2Completed
- Sponsor
- Takeda
- Start
- Dec 2015
- Primary completion
- Oct 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab in metastatic colorectal cancer (mCRC), sponsored by Takeda. Primary endpoints: Dose Limiting Toxicity at 1 month and Progression Free Survival Rate at 6 months. Started Dec 2015; status: completed.
02
Drugs
panitumumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02613221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02613221.